Search

everythinglearnresearchcommunity

for

Search:↓

The user discusses using dutasteride to stop hair loss and bimatoprost for regrowth. They plan to use VEGF with hydrogels for potentially permanent hair follicle improvement and suggest PRP as an alternative.

Verteporfin might reverse severe hair loss but is still in early testing stages. It could be a future option for NW6-7, though expensive.

A 51-year-old on TRT plans to use steroids and is concerned about hair loss, considering topical treatments like Hair Rescue with RU58841 and finasteride, along with Nioxin shampoo. They are cautious about using oral DHT blockers due to potential interactions with steroids like Tren and Anavar.

The conversation discusses whether finasteride would still be necessary if Verteporfin becomes a successful hair loss treatment. It also explores the sensitivity of transplanted hair to DHT and the potential for off-label use of Verteporfin post hair transplant.

The conversation expresses frustration over the lack of progress in hair loss treatments, with specific mentions of Minoxidil, finasteride, and RU58841. Users discuss the slow development of new treatments and the potential of hair transplants.

The conversation discusses potential hair loss treatments focusing on stimulating IGF-1 at the follicle level using growth-factor cocktails and engineered peptides, such as Acetyl Tetrapeptide-3, Copper Tripeptide-1, Oligopeptide-20, Thymosin-β4, and Palmitoyl Tetrapeptide-7. It suggests that device-assisted delivery methods like microneedling may enhance effectiveness.

The user experienced male pattern baldness starting at 18, tried finasteride with no success, and switched to dutasteride, which halted hair loss. Minoxidil had no effect for them, while their brother, who didn't use AR inhibitors, maintained a juvenile hairline and successfully grew a beard with minoxidil, highlighting the unpredictable nature of genetics in hair loss and treatment response.

The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.

The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.

The conversation discusses the potential of Verteporfin, an FDA-approved drug, for hair loss treatment, particularly in combination with microneedling or PRP. Users express hope and curiosity about its application, while some remain cautious due to the need for more extensive testing.

The user experienced significant hair regrowth using KX-826 (pyrilutamide) 0.9% over one year, despite initial shedding phases. They reported no side effects and have stabilized hair loss with consistent use.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

A user stopped using RU58841 after discovering their girlfriend's unplanned pregnancy, expressing concern about potential harm to the baby. Others advised consulting a doctor, waiting for health scans, and considering switching to oral finasteride or natural supplements like saw palmetto.

The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.

The post and conversation are about skepticism towards a new hair loss treatment containing 2-deoxy-D-ribose, copper peptides, and exosomes, with concerns about the legitimacy of the product and its website. The treatment's effectiveness and authenticity are questioned due to lack of testing and transparency.

The user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and ask for advice on shipping within the EU and product quality, while also mentioning their current hair loss treatment involves mixing RU with Stemoxydine and Alfatradiol.

Kintor plans to release pyrilutamide foam and a plant-based Koshine by year-end, with GT20029 progressing in their pipeline. Users are pleased about the absence of propylene glycol (PG) in the new products.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

A 32-year-old male with hair loss cannot use finasteride due to erectile dysfunction and minoxidil due to scalp psoriasis. He seeks alternative treatments for his condition.

A user shared their 11-month experience using a 272 diode red light hat for hair loss, noting decent results despite inconsistent use and no medication. Another user suggested that real treatment like minoxidil or finasteride is necessary for long-term hair maintenance.

The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.

Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user is seeking a new source for RU58841 in the EU after their previous supplier stopped selling it. They mention considering Anagen, Actifolic, Minoxidilmax, and rudirect, and are using a treatment mixing RU58841 with Stemoxydine and Alfatradiol.

A user with hair loss is considering starting a business selling hair loss treatments, including RU58841, low-dose topical finasteride with optional minoxidil and tretinoin, and topical melatonin. They are also contemplating offering Pyrilutamide and other unique topicals, seeking feedback on interest and suggestions for their potential store.

The post discusses a phase 2 trial for HMI-115, a hair loss treatment, in China, specifically seeking volunteers aged 18-65 with Norwood 3 vertex, 4, and 5 hair loss. The conversation includes questions about the specific recruitment criteria and how to volunteer.

A young female diagnosed with Lichen planopilaris (LPP) experienced years of misdiagnosis and ineffective treatments, including a hair transplant and other procedures. She is considering litigation due to the misdiagnosis and has learned that LPP is chronic, hair loss can be stopped with ongoing medication, but lost hair cannot regrow.

CB-03-01 is a topical anti-androgen with low absorption, offering potential as a side-effect-free alternative to Finasteride/Dutasteride for hair loss. It's in stage 2 clinical trials for acne and showing promise for male pattern baldness.